NEO241220C6000
- 0.00
- 0.000.00%
NeoGenomics Newsroom
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $18 to $21
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $18 to $20
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), NeoGenomics (NEO) and Ultragenyx Pharmaceutical (RARE)
NeoGenomics' Strong Financial Performance and Growth Potential Earns Buy Rating
Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
Craig-Hallum Sticks to Their Buy Rating for NeoGenomics (NEO)
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Trevi Therapeutics (TRVI) and DENTSPLY SIRONA (XRAY)
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Announces Target Price $18
NeoGenomics Hold Rating Maintained Amidst Ongoing Legal Challenges and MRD Assay Development Uncertainty
Needham Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $19
Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
Craig-Hallum Remains a Buy on NeoGenomics (NEO)
NeoGenomics Analyst Ratings
Benchmark Reiterates Buy on NeoGenomics, Maintains $18 Price Target
Benchmark Co. Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $18
Analysts Conflicted on These Healthcare Names: American Well (AMWL), Cogent Biosciences (COGT) and NeoGenomics (NEO)
Morgan Stanley Maintains NeoGenomics(NEO.US) With Hold Rating, Raises Target Price to $18
NeoGenomics (NEO) Gets a Hold From Morgan Stanley
Analysts Offer Insights on Healthcare Companies: American Well (AMWL), United Therapeutics (UTHR) and NeoGenomics (NEO)
BofA Securities Initiates NeoGenomics(NEO.US) With Hold Rating